Fountain Medical Development Ltd.
Latest From Fountain Medical Development Ltd.
Recent deals linking Chinese and foreign firms indicate new and bolder views on China’s prospects for cutting-edge oncology and rare disease treatments, helped by recent regulatory changes, but a mix of factors is still at play, veteran executives say.
Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.
Just how much regulatory reforms help fuel biotech investment rush in China? Look no further than active deal flow and hot cash rolling in. The new regulations are all about bringing efficiency to their investment in China, industry insiders say.
Very few people doubt about what China FDA can do to reduce its notorious drug approval backlog, the agency's actual moves and impact to the industry, however, is shocking to many. Meanwhile, a rigorous clinical data review has been expanded to Beijing and Shanghai with local FDA involved.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.